Contraception With a Real Estrogen Contraindication: How Safe Is Progestin-Only, Actually
A migraine-with-aura history and a prior VTE both rule out estrogen outright — but whether progestin-only methods carry meaningful residual risk of their own, or none the guidelines actually recognize, is a genuinely closer question than the safety conversation usually treats it as.
Nadia F., a 34-year-old woman, works as a UX researcher and has managed migraine with visual aura since her early twenties, well-controlled on a triptan for abortive treatment but never fully resolved. Four years ago, a below-knee deep vein thrombosis during a long-haul flight was treated with six months of anticoagulation and has left her, reasonably, wary of anything that touches her clotting risk. She's coming off a copper IUD she had placed two years ago after a difficult, painful insertion she describes directly as something she doesn't want to repeat, and is looking for a reliable alternative she can start without another procedure like it.
Combined estrogen-containing contraception is unambiguously ruled out — both migraine with aura and a personal VTE history are independent, well-established contraindications under the WHO Medical Eligibility Criteria, and having both together isn't a borderline call. What's genuinely contested is what happens one category down: progestin-only methods carry a substantially lower VTE risk profile than estrogen-containing ones because the elevation tracks specifically with estrogen dose, and the WHO MEC lists progestin-only pills, the levonorgestrel IUD, and the implant as Category 1 or 2 (no restriction, or benefits outweigh theoretical/proven risks) even in patients with her combined history — but "substantially lower" and "the guideline doesn't restrict it" are not, on their own, the same claim as "carries no residual risk worth naming," and how much weight that distinction deserves is exactly what today's visit turns on.
Nadia works remotely most weeks and travels for user-research sessions roughly once a month, often on flights long enough that her prior DVT still shapes how she packs and moves on board — compression stockings, scheduled walks down the aisle, a habit she's kept up for four years since the clot regardless of what contraceptive method she's on. She raised her travel pattern herself as a reason she wants real clarity on the actual mechanism behind any residual risk, rather than a blanket reassurance, since it's the kind of detail she feels equipped to manage around once she understands it. Her difficult copper insertion is the only prior data point available and it predicts little about a hormonal device: the pain was mechanical, the same cervix and the same technique apply, and the levonorgestrel changes neither — which makes her strongest objection to the best-scoring option an argument about the procedure rather than the drug.
Contraceptive consult, coming off the copper IUD
I'd approach any hormonal option cautiously here, progestin-only included. Migraine with aura is itself an independent stroke risk factor, on top of her VTE history, not subsumed by it — the two risks stack rather than one absorbing the other. Progestin-only methods carry substantially lower VTE risk than estrogen- containing ones, but "substantially lower" isn't the same claim as "no residual risk," and a copper IUD sidesteps the whole question with the most effective reversible method available.
If she didn't have the migraine-with-aura history — just the VTE — I'd be far more comfortable recommending a progestin-only method without this much hedging.
The WHO MEC categories exist specifically to make this distinction load-bearing, not rhetorical. The VTE and stroke risk elevation tracks with estrogen dose — that's the actual mechanism, not a guideline simplification. Progestin-only pills, the levonorgestrel IUD, and the implant are all Category 1 or 2 even with her combined history. Treating progestin-only as carrying meaningful residual risk overstates what the mechanistic and epidemiologic evidence actually shows.
I'd agree caution is reasonable in the sense of documenting the conversation and her own risk tolerance — but "cautious" shouldn't translate into steering her away from a method the evidence specifically clears, toward a device she's already told us she doesn't want to repeat.
Once the safety question is genuinely this close to resolved — and I think it is, given the MEC categorization the gynecologist named — her own stated preference should carry real weight rather than being treated as secondary to a safety disagreement that's mostly settled. She's told us directly she wants reliability, a low daily burden, and no repeat of a difficult insertion. The levonorgestrel IUD answers all three without asking her to reconsider a device experience she's already described clearly.
Agreed: levonorgestrel IUD placement scheduled, with the neurologist's caution documented directly in the chart as an ongoing point of monitoring rather than a reason to withhold the method — specifically, that any new or changed migraine pattern after placement should prompt a direct reassessment rather than being attributed reflexively to something else. Nadia was told plainly that the safety question had genuine, real disagreement behind it, even though the team ultimately converged on one method.